drugset / Trial / NCT00144703

Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation

NCT00144703

Non-randomizedSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to evaluate the ability of sirolimus to prevent graft versus host disease (GVHD) in patients following stem cell transplant from a related donor.

Timeline

Start
2002-07
Primary completion
2006-11
Completion
2006-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Sirolimus Small molecule Oral
Subject Tacrolimus Small molecule Intravenous